Acute and chronic graft-versus-host disease

Research output: Contribution to journalArticle

Abstract

Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress, was made in many areas.

Original languageEnglish (US)
Pages (from-to)276-281
Number of pages6
JournalCurrent Opinion in Oncology
Volume5
Issue number2
StatePublished - 1993

Fingerprint

Graft vs Host Disease
Histocompatibility Antigens
Thalidomide
Interleukin-1
Tumor Necrosis Factor-alpha
Cytokines
T-Lymphocytes
Therapeutics
Research

ASJC Scopus subject areas

  • Cancer Research

Cite this

Acute and chronic graft-versus-host disease. / Vogelsang, Georgia Boyce.

In: Current Opinion in Oncology, Vol. 5, No. 2, 1993, p. 276-281.

Research output: Contribution to journalArticle

@article{835d57bba1b843f5aedd72715847cc84,
title = "Acute and chronic graft-versus-host disease",
abstract = "Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress, was made in many areas.",
author = "Vogelsang, {Georgia Boyce}",
year = "1993",
language = "English (US)",
volume = "5",
pages = "276--281",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Acute and chronic graft-versus-host disease

AU - Vogelsang, Georgia Boyce

PY - 1993

Y1 - 1993

N2 - Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress, was made in many areas.

AB - Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress, was made in many areas.

UR - http://www.scopus.com/inward/record.url?scp=0027516895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027516895&partnerID=8YFLogxK

M3 - Article

C2 - 8457614

AN - SCOPUS:0027516895

VL - 5

SP - 276

EP - 281

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -